CA
CASI Pharmaceuticals, Inc.
CASIF · OTC
$0.13 +0.00% (+$0.00)
1M +0.00%
Market Cap $2.65M
P/E Ratio -
Div. Yield -
ROE -
Piotroski F-Score Weak
3/9Valuation
100 /100
Cheap P/S 0.13x
EV/EBITDA N/A
P/B N/A
Growth
9 /100
Declining Book val. growth 72.02%
Rev. growth 1.84%
FCF growth N/A
Profitability
22 /100
Weak Net margin 218.55%
Op. margin 190.98%
FCF margin 0.00%
Quality
74 /100
Excellent ROA 208.70%
Asset turnover 0.95x
ROIC 759.62%
Debt
0 /100
High Int. coverage -100.15x
Current ratio 0.15x
Net debt/EBITDA N/A
Stability
35 /100
Moderate Rev. volatility 35.61%
EPS volatility 31.04%
Profitable years 0
Bulios Scoring popisuje kvalitu a minulost firmy, ne budoucí výnos. Vysoké skóre není nákupní signál. Zjistit více
Zeptejte se StockBota na CASIF
Online
Sector
Healthcare
Industry
Biotechnology
CEO
David A. Cory
Employees
214
Headquarters
Beijing
Nadcházející události
25 ZÁŘ
Earnings
Upcoming earnings report
13 LIS
Earnings
Upcoming earnings report